Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy at-term parturients undergoing elective cesarean delivery under spinal anesthesia~Exclusion Criteria:~* Emergency cesarean delivery~* Respiratory disease~* significant comorbidities: preeclampsia, insulin-dependent diabetes mellitus~* obstructive sleep apnea~* body mass index \> 35kg/m2~* \<18yrs~* documented intolerance or allergy to systemic or neuraxial opioids~* patient with a history of chronic opioid or current use of opioids

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Hydromorphone 25mcg (Type: ACTIVE_COMPARATOR): The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
- Hydromorphone 50mcg (Type: ACTIVE_COMPARATOR): The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
- Hydromorphone 100mcg (Type: ACTIVE_COMPARATOR): The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).